Dear Editor,The epidermal growth factor receptor(EGFR),one member of the ErbB family of receptor tyrosine kinases,has been implicated in various epithelial malignancies.As a clinically validated target,both small-mole...Dear Editor,The epidermal growth factor receptor(EGFR),one member of the ErbB family of receptor tyrosine kinases,has been implicated in various epithelial malignancies.As a clinically validated target,both small-molecule tyrosine kinase inhibitors and antibody-based drugs have been approved by regulatory agencies.Anti-EGFR antibodyci rug conjugates(ADCs)could kill target tumor cells irrespective of EGFR signaling.However,cancer patients treated with EGFR-targeted antibody therapy eventually develop acquired epitope substitutions such as S492R,G465R,G465E,and 1491M.展开更多
基金supported by the National Natural Science Foundation of China(Grant No.82073750)National Science and Technology Major Projects for"Major New Drugs Innovation and Development"(2017ZX09302006002)+3 种基金Key research and development project of Zhejiang Province(No.2O18CO3O22)National Key R&D Program of China(No.2017YFE0102200)the Fundamental Research Funds for the Central Universities(No.2020QNA7005)Zhejiang Province"Qianjiang Talent Plan".
文摘Dear Editor,The epidermal growth factor receptor(EGFR),one member of the ErbB family of receptor tyrosine kinases,has been implicated in various epithelial malignancies.As a clinically validated target,both small-molecule tyrosine kinase inhibitors and antibody-based drugs have been approved by regulatory agencies.Anti-EGFR antibodyci rug conjugates(ADCs)could kill target tumor cells irrespective of EGFR signaling.However,cancer patients treated with EGFR-targeted antibody therapy eventually develop acquired epitope substitutions such as S492R,G465R,G465E,and 1491M.
